Mass Spectrometry-based Bioanalysis Platform
As pipeline molecules become increasingly complex, traditional ligand-binding assays may not always provide the level of characterization required. WuXi Biology’s Mass Spectrometry-based Bioanalysis Platform delivers robust, sensitive analysis for small to large molecules across drug discovery.
Our proven Mass Spectrometry capabilities include:
🔷 ADC Characterization – Precise Drug-to-Antibody Ratio (DAR) determination, site-specific conjugation analysis, epitope mapping, and glycan structure elucidation.
🔷 Covalent Drug Screening – Validation of irreversible binding kinetics and specificity, identification of covalent binding sites, and assessment of in vivo target engagement.
🔷 Native Mass Spectrometry – Preservation of non-covalent interactions to ensure structural integrity.
🔷 Targeted Protein Mass Spectrometry – Absolute quantification of low-abundance protein biomarkers in complex biological matrices.
Backed by advanced Mass Spectrometry instrumentation and experience from more than 300 projects, our platform delivers fast, reliable, and high-quality data to advance your drug discovery research.
Contact us to learn more about our Mass Spectrometry-based Bioanalysis capabilities.
